Suppr超能文献

大鼠鼻内给予尼卡地平

Intranasal delivery of nicardipine in the rat.

作者信息

Visor G C, Bajka E, Benjamin E

出版信息

J Pharm Sci. 1986 Jan;75(1):44-6. doi: 10.1002/jps.2600750110.

Abstract

The intranasal absorption of nicardipine hydrochloride was characterized in an in vivo rat model system in which the normal mechanisms of mucociliary clearance and drainage of an instilled dose were not physically altered. The results obtained in this manner, therefore, are expected to be predicative of the delivery and absorption dynamics exhibited in the nasal mucosa of primates and humans. Intranasal delivery of nicardipine was studied in male rats using this model on single-dose administration of 1.0 mg/kg, and compared with both oral and intravenous administration. The effect of the addition of a viscosity agent, hydroxyethyl cellulose, on plasma levels following nasal delivery was also examined. Nicardipine plasma levels were determined by a rapid and specific reversed-phase HPLC method with electrochemical detection that employed nifedipine as an electroactive internal standard in the analysis. The limit of quantitation for nicardipine at 1.0 V versus Ag/AgCl was 8 ng/mL and the linear dynamic range was 15-150 ng/mL. Following intravenous administration the area under the plasma concentration curve was 5110 ng . min/mL as compared to 3730 ng . min/mL following intranasal dosing. This corresponds to a bioavailability of 73%. The addition of a viscosity agent to the nasal formulation was found to give a slight but statistically insignificant increase in the systemic availability (77%). Plasma levels of nicardipine following oral administration (1.0 mg/kg) were determined to be below the limit of quantitation of the analytical technique. These results therefore suggest that nasal delivery of nicardipine is a viable and efficient route of administration.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

在一个体内大鼠模型系统中对盐酸尼卡地平的鼻内吸收进行了表征,在该模型中,滴注剂量的正常黏液纤毛清除和引流机制未发生物理改变。因此,以这种方式获得的结果有望预测灵长类动物和人类鼻黏膜中的递送和吸收动力学。使用该模型在雄性大鼠中研究了尼卡地平的鼻内递送,单次给药剂量为1.0 mg/kg,并与口服和静脉给药进行了比较。还研究了添加黏滞剂羟乙基纤维素对鼻内给药后血浆水平的影响。通过快速且特异的反相高效液相色谱法并采用电化学检测来测定尼卡地平的血浆水平,该方法在分析中使用硝苯地平作为电活性内标。相对于Ag/AgCl,尼卡地平在1.0 V时的定量限为8 ng/mL,线性动态范围为15 - 150 ng/mL。静脉给药后血浆浓度曲线下面积为5110 ng·min/mL,而鼻内给药后为3730 ng·min/mL。这对应于73%的生物利用度。发现向鼻用制剂中添加黏滞剂会使全身利用率略有增加,但在统计学上无显著差异(77%)。口服给药(1.0 mg/kg)后尼卡地平的血浆水平低于分析技术的定量限。因此,这些结果表明尼卡地平的鼻内递送是一种可行且有效的给药途径。(摘要截断于250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验